Phase IIB/III trial of tenecteplase in acute ischemic stroke: Results of a prematurely terminated randomized clinical trial

Stroke

Volumn 41, Issue 4, 2010, Pages 707-711

  Haley, E Clarke ^a   Thompson, John L P ⁱ   Grotta, James C ^b   Lyden, Patrick D ^c   Hemmen, Thomas G ^c   Brown, Devin L ^d   Fanale, Christopher ^e   Libman, Richard ^f   Kwiatkowski, Thomas G ^f   Llinas, Rafael H ^g   Levine, Steven R ^h   Johnston, Karen C ^a   Buchsbaum, Richard ⁱ   Levy, Gilberto ⁱ   Levin, Bruce ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e Colorado Neurological Institute ^*  (United States)

^f LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h MOUNT SINAI MEDICAL CENTER   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Acute ischemic stroke; Tenecteplase; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TENECTEPLASE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; STANDARD; STROKE PATIENT; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77950251479     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.572040     Document Type: Article

References (9)

1. Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46:56-60
2. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet. 1999;354:716-722.
3. Haley EC, Lyden PD, Johnston KC, Hemmen TM; the TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005;36:607-612.
4. Brown DL, Johnston KC, Wagner DP, Haley EC. Predicting major neurological improvement with intravenous tissue plasminogen activator treatment of stroke. Stroke. 2004;35:147-150.
5. Lyden P, Raman R, Liu L, Grotta J, Broderick J, Olson S, Shaw S, Spilker J, Meyer B, Emr M, Warren M, Marler J. NIHSS training and certification using a new digital video disk is reliable. Stroke. 2005;36:2446-2449.
6. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
7. Adams HP, del Zoppo G, Alberts MJ, Bhatt D, Brass L, Furlan A, Grubb RL, Hiagshida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdiks EFM. Guidelines for the early management of adults with ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke. 2007;38:1655-1711.
8. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DS, Marsh EE. Classification subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
9. Parsons MW, Miteff F, Spratt N, Loisell A, Attia J, Levi CR. Acute ischemic stroke. Imaging guided tenecteplase treatment in an extended time window. Neurology. 2009;72:915-921.